Stirred & Shaken: Navigating Potential Disruptions at the U.S. National Institutes of Health
Speakers
The U.S. National Institutes of Health has long underpinned America’s biomedical leadership. But the Trump administration’s sudden 15% cap on indirect cost reimbursements, down from 40–75%, has sent shockwaves through academic research, biopharma, and medtech.
In this on-demand webinar, Clarivate experts unpack the $4 billion cut’s far-reaching impacts—from therapeutic pipeline erosion and medtech market volatility to challenges for HBCUs and safety risks in NIH-affiliated clinical trials.
Watch to explore:
- SBIR/STTR delays and early-stage discovery risks
- Sequencing market shakeouts and reagent pricing shifts
- Legal challenges from 22 states
- The future of VC in neglected diseases
- How academic medical centers and smaller institutions are adapting
